

Place: National Institutes of Health, 31 Center Drive, Building 31, Conference Room 6, Bethesda, MD 20892.

Closed: 03:00 p.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 31 Center Drive, Building 31, Conference Room 6, Bethesda, MD 20892.

Contact Person: Donna Brooks, Executive Officer, National Institutes of Health, National Institute on Minority Health and Health Disparities, 6707 Democracy Blvd., Suite 800, Bethesda, MD 20892, (301) 435-2135, brooksds@mail.nih.gov.

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxis, hotel, and airport shuttles, will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Dated: May 4, 2015.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015-11062 Filed 5-7-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel, SBIR Contract Review.

Date: June 17, 2015.

Time: 12:00 p.m. to 3:30 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Two Democracy Plaza, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Dennis Hlasta, Ph.D., Scientific Review Officer, 6707 Democracy Boulevard, Suite 952, Bethesda, MD 20892, 301-451-4794, hlastadj@mail.nih.gov.

Dated: May 4, 2015.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015-11063 Filed 5-7-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Announcement of Requirements and Registration for the Opioid Overdose Prevention Challenge

AGENCY: SAMHSA, HHS.

ACTION: Notice.

Authority: 15 U.S.C. 3719.

SUMMARY: In summarizing the challenge that will be issued by your agency, please answer the following four questions:

(1) What action is being taken?

The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued a challenge to help prevent opioid overdose and support recovery through innovative, software-based solutions that help people know the signs of opioid use, understand what to do if a family member or friend overdoses on heroin or opioid pain medications, and support

treatment for opioid addiction and recovery.

(2) Why is this action necessary?

There were 17,000 deaths from opioids in 2010, double the deaths in 2001. Use of prescription opioids has quadrupled. Death by opioid overdose is preventable. SAMHSA hopes to help prevent deaths from opioid overdose, and support treatment and recovery for individuals with an opioid substance use disorder.

(3) What is the objective of the challenge?

To prevent deaths from opioid overdose, and support treatment and recovery for individuals with an opioid substance use disorder by providing resources and information on understanding the signs of overdose, how to respond to an overdose, information about opioid use, treatment, and recovery.

(4) What is the intended effect of this action?

A reduction in the number of individuals dying from opioid overdose. SAMHSA is seeking solutions to this problem through cost-effective, portable, technology-based products that effectively reach a diverse population of friends and family concerned about opioid use by someone they know. Technology-based products may include, but are not limited to, web applications, mobile apps, and Web sites.

DATES: The challenge starts on June 1, 2015 10:00 a.m. ET. The challenge ends on July 29, 2015 11:59 p.m. ET.

FOR FURTHER INFORMATION CONTACT: Dina Passman, Public Health Advisor, SAMHSA/CSAT/PMB, 1 Choke Cherry Road, Room 5-1070, Rockville, MD, Phone: (240) 276-2854, Email: Dina.Passman@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION:

Subject of Challenge Competition: Opioid Overdose Prevention.

Eligibility Rules for Participating in the Competition:

To satisfy the mandatory provisions of the Competes Act, use the following language:

“To be eligible to win a prize under this challenge, an individual or entity—

(1) Shall have registered to participate in the competition under the rules promulgated by [the issuing agency];

(2) Shall have complied with all the requirements under this section;

(3) In the case of a private entity, shall be incorporated in and maintain a primary place of business in the United States, and in the case of an individual,